Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine, out of two doses (a standard and a low dose) compared
to placebo, the optimal and minimal dose of an intravenously administered single bolus of
tranexamic acid(TA) to reduce blood loss when administered during cesarean section(CS).
Tranexamic acid is an antifibrinolytic agent, which causes a reversible and competitive
blockade of the lysine binding sites on plasminogen molecules. It is a synthetic analog of
the amino acid lysine and its action is to reduce blood loss. TA is widely in use in the
field of obstetrics. Both antepartum and postpartum hemorrhage(PPH) is being treated by TA
extensively. One study demonstrated for the first time that TA administered to women with
overt PPH decreases blood loss and maternal morbidity. Prevention of PPH is another
indication where TA has been used. Varied doses of TA ranging from 1 mg/kg to more than 100
mg/kg have been used in various surgeries. Even in studies involving CS, the doses used were
either a bolus of 1 gm or 10 mg/kg intravenously.
The dose of 1 g or 10 mg/kg is commonly used prophylactically before CS, Because of the lack
of data on lower doses and TA pharmacokinetics, a low 0.5-g dose should be tested.